Date: 2016-11-08
Type of information: Company acquisition
Acquired company: AccelLAB (Canada)
Acquiring company: CiToxLAB (France)
Amount: undisclosed
Terms:
- • On November 8, 2016, CiToxLAB, a leading player among preclinical CROs, announced the acquisition of AccelLAB, a Canadian CRO specialized in the pre-clinical assessment of new medical devices.
- Through this acquisition, CiToxLAB Group reinforces its position in the non-clinical CRO arena and enlarges its services portfolio to medical devices. Following this acquisition, Dr. Guy Leclerc remains the Managing Director of AccelLAB.
- Dr. Jean-François Le Bigot, Chairman and CEO of CiToxLAB Group stated: “We identified AccelLAB as a strategic target to make our group a more global services player in the Life Sciences Services arena. Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers in particular in the cardiovascular, orthopedic fields and more generally in the regenerative medicine."
- With six facilities located in France (Evreux, Saint-Nazaire), Canada (Montreal), Denmark (Copenhagen) and Hungary (Veszprem), CiToxLAB offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device and chemical companies worldwide. The group carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers.
Details:
- AccelLAB was founded in 2004 by Dr. Guy Leclerc, an Interventional Cardiologist who headed the department of Cardiology and Cardiac Surgery of the Centre Hospitalier de l’Université de Montreal (CHUM). As an interventional cardiologist practitioner, Guy Leclerc has been a pioneer in applying what we call today translational research in the field of medical devices, helping client companies in the development of new cardiac stents, valves, pacemakers, etc.
- AccelLAB has a staff of around 100 people and the facilities include operating rooms, in particular for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.
- The services were more recently enlarged to other areas such as orthopedic, ENT (Ear, Nose and Throat) and dermatology specialties.
- With AccelLAB joining the Group, CiToxLAB provides efficiency and safety studies in the field of medical devices (cardiology, ENT, orthopedics, dermatology and regenerative medicine).
- A partnership with Stemina (Madison, USA) allows the Group to offer screening services using human embryonic stem cell models.
Related: Technology - Services - Medical devices
Is general: Yes
